BioCatalyst

CRDF — Cardiff Oncology, Inc. catalysts

1 verified catalyst event(s) for Cardiff Oncology, Inc. (ticker CRDF). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-11-01 — Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-11 (month)
in 4mo
ESTIMATED
 READOUT
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and B
Phase 2 · Metastatic Colorectal Cancer, CRC
 CRDF Cardiff Oncology, Inc. Onvansertib, FOLFIRI, Bevacizumab, FOLFO ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.